Belantamab mafodotin (belamaf), another ADC consisting of an anti-B-cell maturation antigen (BCMA) mAb and the active cytotoxic drug monomethyl auristatin F (MMAF), was approved for the therapy of relapsed/refractory multiple myeloma (RRMM) in August 2020 by the FDA [8]. The gene discussed is TNFRSF17; the disease is AL amyloidosis.